Home > Products

Products

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
A369 Tanezumab Biosimilar(Anti-NGF / bNGF Reference Antibody) Featured Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia.
A370 Fasinumab Biosimilar(Anti-NGF / bNGF Reference Antibody) Featured Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies.
A371 MEDI-578 Biosimilar(Anti-NGF / bNGF Reference Antibody) Featured
A372 Fulranumab Biosimilar(Anti-NGF / bNGF Reference Antibody) Featured Fulranumab is a human IgG2 monoclonal antibody against nerve growth factor (NGF) and can be used for the research of pain.
A373 AS2886401-00 Biosimilar(Anti-NGF / bNGF Reference Antibody ) Featured
A374 Monalizumab Biosimilar(Anti-NKG2A / CD94 Reference Antibody) Featured Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
A375 Tesnatilimab Biosimilar(Anti-NKG2D / CD314 Reference Antibody) Featured Tesnatilimab is a human IgG4 monoclonal antibody that acts on the immune activating receptor NKG2D and has potential immunomodulatory and anti-inflammatory activity. Tesnatilimab can be used in the study of inflammatory bowel disease (IBD).
A376 Abbott patent anti-NGR Biosimilar(Anti-Nogo Receptor / NgR Reference Antibody) Featured
A377 Pfizer patent anti-Notch1 Biosimilar(Anti-NOTCH1 Reference Antibody) Featured
A378 Tarextumab Biosimilar(Anti-NOTCH3 Reference Antibody) Featured Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody. Tarextumab shows anti-tumor activity.
DC67002 Genentech patent anti-Notch Featured
A380 Vesencumab Biosimilar(Anti-NRP1 / VEGF165R / CD304 Reference Antibody) Featured Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer.
A381 Uliledlimab Biosimilar(Anti-NT5E / CD73 Reference Antibody) Featured Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer.
A382 Oleclumab Biosimilar(Anti-NT5E / CD73 Reference Antibody) Featured Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity.
A383 Mupadolimab Biosimilar(Anti-NT5E / CD73 Reference Antibody) Featured Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells.
A384 Amgen patent anti-ORAI1 Biosimilar(Anti-Orai1 Reference Antibody) Featured
A385 Vixarelimab Biosimilar(Anti-OSMR Reference Antibody) Featured Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash.
A386 ASK8007 Biosimilar(Anti-Osteopontin Reference Antibody) Featured
A387 Janssen patent anti-CD200R1 Biosimilar(Anti-OX2R / CD200R1 Reference Antibody) Featured
A388 Orticumab Biosimilar(Anti-oxLDL Reference Antibody) Featured Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement.
A389 Okayama U. patent anti-oxLDL Biosimilar(Anti-oxLDL Reference Antibody) Featured
A390 Zelminemab Biosimilar(Anti-PAC1 Reference Antibody) Featured Zelminemab (AMG-301) is a humanized monoclonal antibody that inhibits PACAP type I (PAC1) receptor.
A391 Lilly patent anti-PACAP Biosimilar(Anti-PACAP38 Reference Antibody) Featured
A392 Amgen patent anti-PAR-2 Biosimilar(Anti-PAR2 Reference Antibody) Featured
A393 PAR650097 Biosimilar(Anti-PAR2 Reference Antibody) Featured
A394 Regeneron patent anti-PAR-2 Biosimilar(Anti-PAR2 Reference Antibody) Featured
A395 U.Penn. patent anti-PCLA Biosimilar(Anti-PCLA Reference Antibody) Featured
A396 Recaticimab Biosimilar(Anti-PCSK9 Reference Antibody) Featured Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Recaticimab can bind to PCSK9 and mediate its degradation, increasing the level of low-density lipoprotein (LDL) receptors on the surface of liver cells, reducing the level of LDL in plasma, thereby lowering blood lipids. Recaticimab can be used for the study of hypercholesterolemia.
A397 Ralpancizumab Biosimilar(Anti-PCSK9 Reference Antibody) Featured Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke.
A398 RG-7652 Biosimilar(Anti-PCSK9 Reference Antibody) Featured

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X